Clinical trial NCT03317743: Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Official title: Open-label, Phase I Clinical Trial to Identify Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Anti-cancer Efficacy of NOV140101(IDX-1197HCl) in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumors
Keywords: 1197
IDX-1197
venadaparib
Lead sponsor: Idience Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: IlDong Pharmaceutical Co Ltd
name: National OncoVenture
First posted: 2017-10-23
Enrollment: 32
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: the purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NOV140101 (IDX-1197).

Detailed description: This is an open-label, Phase 1 dose escalation study of NOV140101 (IDX-1197) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of IDX-1197 in patients with advanced solid tumors after failure of standard of care. DLTs will be assessed as the primary endpoint in this trial.

Eligibility criteria: Inclusion Criteria:

* ≥19 year old patients with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors
* Life expectancy ≥12 weeks
* Women of childbearing potential must have a negative pregnancy test outcome
* ECOG performance status ≤2
* Lesions measured by tumor markers or CT/MRI and evaluable according to RECIST v1.1
* Patient must have adequate organ function as indicated by the following laboratory values independent of transfusion within 2 weeks:

  1. ANC ≥ 1,500/mm³
  2. Platelet count ≥ 100,000/mm³
  3. Hemoglobin ≥ 9.0g/dL
  4. Serum creatinine ≤ 1.5×ULN
  5. Total bilirubin ≤ 1.5×ULN
  6. AST, ALT ≤ 3×ULN (≤ 5×ULN for patients with liver metastasis or liver cell cancer)
  7. PT and aPTT ≤ 1.5×ULN
  8. UPC \< 1.0 g/g (one re-test is allowed if positive (≥ 1))
* Patients must provide written informed consent to voluntary participation in this study.

Exclusion Criteria:

* History of hypersensitivity reactions to any of the components of the investigational product or other drugs of the same class
* New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled hypertension (systolic/diastolic blood pressure \>140/90mmHg), or other clinically significant cardiovascular abnormalities in the opinion of the investigator
* Uncontrolled cardiac arrhythmia
* Acute coronary syndrome (unstable angina pectoris or myocardial infarction) within the past 6 months
* Major electrocardiogram (ECG) abnormalities in the opinion of the investigator
* Severe infection or severe traumatism
* Pneumonia or respiratory symptoms, such as dyspnea, cough, and fever, requiring treatment and other conditions likely to be accompanied by hypoxemia
* History of drug or alcohol abuse within the past 3 months
* Symptomatic or uncontrolled central nervous system (CNS) metastasis
* Less than 4 weeks have elapsed since a major surgery and 2 weeks have elapsed since a minor surgery
* Radiotherapy, hormone therapy, or chemotherapy within 2 weeks prior to baseline from which toxicities not recovered to ≤grade 1
* \>4 weeks of persistent Grade 3 (NCI-CTCAE v4.03) hematologic toxicities from prior anticancer treatment
* History of myelodysplastic syndrome (MDS) or pre-treatment cytogenetic test results indicative of the risk of MDS or acute myelocytic leukemia
* Ongoing or anticipated treatment with antiplatelet drugs (aspirin, clopidogrel, etc.) or anticoagulant drugs (warfarin, heparin, etc.) during the study
* Requiring continuous treatment with systemic NSAIDs or systemic corticosteroids
* Ongoing or past treatment with immunosuppressants within 14 days prior to the first dose of study treatment, except for intranasal, inhaled, topical, or locally injected (e.g., intraarticular injection) steroids
* History of serious gastrointestinal bleedings within 12 weeks prior to screening or presence of diseases that may affect oral drug absorption (e.g., malabsorption syndrome, active peptic ulcer)
* History of human immunodeficiency virus infection or active hepatitis B or C infection or ongoing uncontrolled chronic infectious disease
* Pregnant or lactating women or patients planning to become pregnant during the study
* Participation in another clinical trial within 30 days prior to screening
* Individual considered ineligible for this study for other reasons, in the opinion of the investigator

Primary outcomes:
measure: Dose Limiting Toxicities (DLTs)
timeFrame: Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-21)
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
state: Songpa-gu
Study officials:
References: